At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
SNF472drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients
In Brief
A Phase 2 clinical trial evaluating SNF472 for Calciphylaxis and Calcific Uremic Arteriolopathy. Completed, enrolled 14 participants across 3 sites in 2 countries.
Detailed Summary
To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCalciphylaxis, Calcific Uremic Arteriolopathy
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedJun 2016
Primary CompletionNov 2017
TodayJul 2026
First PostedJun 3, 2016
Enrollment StartMay 1, 2016
Primary CompletionNov 15, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.1 years ago
Interventions
SNF472drug
SNF472 for calciphylaxis